FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 350:211-212 January 15, 2004 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Return to Search Result Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Stone, G. W. PubMed Citation

A second drug-eluting coronary stent. Another drug for erectile dysfunction. A sixth statin (or seventh, counting cerivastatin). Medical journals seem filled with research articles that induce a sense of déjà vu. Readers wonder, "Have I read this paper before?" No, that was a similar study of a similar product.

Critics of the pharmaceutical and medical-device industry argue that "me-too" products cause problems for medicine beyond confusion. They assert that these market latecomers often differ trivially from earlier products and that the billions of dollars spent marketing me-too products could be spent in better ways, such as developing orphan drugs for . . . [Full Text of this Article]

Source Information

From Partners Healthcare System and Harvard Medical School, Boston.

Related Letters:

"Me-Too" Products — Friend or Foe?
Frothingham R., Relman A. S., Lee T. H.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:2100-2101, May 13, 2004. Correspondence

This article has been cited by other articles:

• Scott, D. L, Cope, A. (2009). New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?. Ann Rheum Dis 68: 767-769 [Full Text]  
• Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Doloresco, F., Martin, P. K., Blake, S., Matusiak, L., Hunkler, R. J., Schumock, G. T. (2009). Projecting future drug expenditures--2009. Am J Health Syst Pharm 66: 237-257 [Abstract] [Full Text]  
• Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Doloresco, F., Grim, P., Hunkler, R. J., Hontz, K. M., Schumock, G. T. (2008). Projecting future drug expenditures--2008. Am J Health Syst Pharm 65: 234-253 [Abstract] [Full Text]  
• Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Schumock, G. T., Grim, P., Hunkler, R. J., Hontz, K. M. (2007). Projecting future drug expenditures--2007. Am J Health Syst Pharm 64: 298-314 [Abstract] [Full Text]  
• Mintzberg, H. (2006). Patent nonsense: Evidence tells of an industry out of social control.. CMAJ 175: 374-374 [Full Text]  
• Austin, P. C, Mamdani, M. M, Juurlink, D. N (2006). How Many "Me-Too" Drugs Are Enough? The Case of Physician Preferences for Specific Statins. The Annals of Pharmacotherapy 40: 1047-1051 [Abstract] [Full Text]  
• Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Schumock, G. T., Grim, P., Hunkler, R. J., Hontz, K. M. (2006). Projecting future drug expenditures--2006. Am J Health Syst Pharm 63: 123-138 [Abstract] [Full Text]  
• Moldrup, C. (2005). No cure, no pay. BMJ 330: 1262-1264 [Full Text]  
• Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Hunkler, R. J., Hontz, K. M. (2005). Projecting future drug expenditures--2005. Am J Health Syst Pharm 62: 149-167 [Abstract] [Full Text]  
• (2004). Slow-Release, Paclitaxel-Eluting Stent Limits Restenosis. Journal Watch Cardiology 2004: 9-9 [Full Text]  
• Frothingham, R., Relman, A. S., Lee, T. H. (2004). "Me-Too" Products -- Friend or Foe?. NEJM 350: 2100-2101 [Full Text]  
• (2004). Slow-Release, Paclitaxel-Eluting Stent Limits Restenosis. Journal Watch Cardiology 2004: 1-1 [Full Text]